Close
Close

Anti-GD2 KIR CAR (3F8) Vector (XS-1122-YF458)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-GD2 KIR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human GD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv (3F8) of anti-GD2 antibody linked to KIR2DS2 TM & ICD and DAP12. The vector product was designed for the discovery and development of cellular therapy against Neuroblastoma. This KIR signaling is designed to prolong KIR-CAR T cells' efficacy period by coupling the receptor chains during activation and decoupling them during rest, avoiding T cell exhaustion even in challenging solid-tumor environments.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • GD2
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Neuroblastoma
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-KIR2DS2 TM&ICD-2A-DAP12
  • Discription of Signaling Cassetes
  • The dual binding and signal chains are designed to come together to form a single receptor complex when bound to a tumor target. Dual chain signaling provides prolonged T cell activation even in challenging solid-tumor environments. KIR CAR combines the power of NK cell KIR receptors with the long-term durability of T cells, resulting in a long-lasting and powerful anti-cancer efficacy. KIR CAR-T cells maintained activation and potent cytotoxic activities in solid tumors compared with the CD28 and 4-1BB co-stimulated CD3-ζ -based traditional CAR T cells. The DAP12 signal functions as both activation and co-stimulation for T cells, circumventing the CD3-ζ pathway to allow prolonged KIR-CAR function.

Target

  • Clone
  • 3F8
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • Ganglioside GD2
  • Synonyms
  • GD2 ganglioside; GD2
  • Introduction
  • Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is overexpressed across a wide range of tumors. Disialoganglioside GD2 can be considered a tumor-associated antigen and well-suited as a target for cancer therapy. Disialoganglioside GD2 is implicated in tumor development and malignant phenotypes through enhanced cell proliferation, motility, migration, adhesion, and invasion, depending on the tumor type. This provides a rationale for targeting disialoganglioside GD2 in cancer therapy with the development of anti-GD2 monoclonal antibodies and other therapeutic approaches.

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-GD2 KIR CAR (scFv-KIR2DS2-DAP12, 3F8), pCDCAR1 (XS-1122-YF458). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR-MA Vector Products

CAR Vector Products

CAR mRNA

CAR-MA Cell Products

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout